Table 1.
Pre-treatment characteristics of the patients.
| Patient with doxorubicin treatment | Patients without any drug treatment | All patients | |
|---|---|---|---|
| Number | 363 | 321 | 684 |
| Age | |||
| <=50 | 173 (48%) | 71 (22%) | 244 (36%) |
| >50 | 189 (52%) | 240 (77%) | 429 (64%) |
| Mean (SD) | 52 (10) | 62 (14) | 56 (13) |
| Unknown | 1 | 10 | 11 |
| Nodal status | |||
| Positive | 238 (66%) | 152 (48%) | 390 (57%) |
| Negative | 122 (33%) | 158 (49%) | 280 (41%) |
| Unknown | 3 (1%) | 11 (3%) | 14 (2%) |
| T stage | |||
| 1 | 73 (21%) | 79 (25%) | 152 (22%) |
| 2 | 233 (64%) | 177 (55%) | 410 (60%) |
| 3 | 52 (14%) | 41 (13%) | 93 (14%) |
| 4 | 5 (1%) | 22 (7%) | 27 (4%) |
| Unknown | 0 (0%) | 2 (0%) | 2 (0%) |
| Pathologic stage | |||
| 1 | 36 (10%) | 59 (18%) | 95 (14%) |
| 2 | 213 (59%) | 174 (54%) | 387 (57%) |
| 3 | 108 (30%) | 67 (21%) | 175 (26%) |
| 4 | 2 (0%) | 9 (3%) | 11 (1%) |
| Unknown | 4 (1%) | 12 (4%) | 16 (2%) |
| ER Status | |||
| Positive | 244 (67%) | 225 (70%) | 469 (69%) |
| Negative | 106 (29%) | 79 (25%) | 185 (27%) |
| Unknown | 13 (4%) | 17 (5%) | 30 (4%) |
| PR Status | |||
| Positive | 209 (58%) | 188 (59%) | 397 (58%) |
| Negative | 139 (38%) | 115 (36%) | 254 (37%) |
| Unknown | 15 (4%) | 18 (5%) | 33 (5%) |
| HER2 Status | |||
| Positive | 45 (12%) | 61 (19%) | 106 (15%) |
| Negative | 207 (57%) | 144 (45%) | 351 (51%) |
| Unknown | 111 (31%) | 116 (36%) | 227 (34%) |